Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2982772 in Moderate to Severe Rheumatoid Arthritis
2016-000912-13Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GSK2982772 with Placebo (2 arms). Primary endpoints: Safety and tolerability of GSK2982772 60 mg three times daily and Plasma concentrations of GSK2982772 (PK) with 60 mg three times daily dosing. Started Jun 2016; status: completed.
02
Drugs
GSK2982772
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-000912-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000912-13.